Buyout funds including KKR and Permira are lining up preliminary bids worth up to 2 billion euros ($2.24 billion) for Spain’s IVI-RMA, sources told Reuters, amid growing demand for companies offering fertility treatment in Europe.
Bain Capital, CVC Capital Partners, Carlyle and PAI Partners are also looking to submit offers for a controlling stake in the Spanish group ahead of a deadline for non-binding offers in late February, the sources said on condition of anonymity.
The firm, which manages more than 75 clinics and 28 labs in nine countries, could be valued at between 16 and 17 times its core earnings of 120 million euros, one of the sources said.
EQT, meanwhile, sold its reproductive genetic testing services provider Igenomix to Swedish medical technology group Vitrolife in a deal worth 1.25 billion euros.
Read more: Reuters
